# Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy

> **NCT02769169** · PHASE2,PHASE3 · TERMINATED · sponsor: **Sun Yat-sen University** · enrollment: 5 (actual)

## Conditions studied

- Polypoidal Choroidal Vasculopathy

## Interventions

- **DRUG:** Lucentis® (Raibizumab) double-dose
- **DRUG:** Lucentis® (Raibizumab) regular-dose

## Key facts

- **NCT ID:** NCT02769169
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-01
- **Primary completion:** 2018-09-12
- **Final completion:** 2018-12-15
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** study protocol changed
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02769169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02769169, "Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02769169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*